<code id='0667CDAE7F'></code><style id='0667CDAE7F'></style>
    • <acronym id='0667CDAE7F'></acronym>
      <center id='0667CDAE7F'><center id='0667CDAE7F'><tfoot id='0667CDAE7F'></tfoot></center><abbr id='0667CDAE7F'><dir id='0667CDAE7F'><tfoot id='0667CDAE7F'></tfoot><noframes id='0667CDAE7F'>

    • <optgroup id='0667CDAE7F'><strike id='0667CDAE7F'><sup id='0667CDAE7F'></sup></strike><code id='0667CDAE7F'></code></optgroup>
        1. <b id='0667CDAE7F'><label id='0667CDAE7F'><select id='0667CDAE7F'><dt id='0667CDAE7F'><span id='0667CDAE7F'></span></dt></select></label></b><u id='0667CDAE7F'></u>
          <i id='0667CDAE7F'><strike id='0667CDAE7F'><tt id='0667CDAE7F'><pre id='0667CDAE7F'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:73368
          Johnson & Johnson logo. -- health coverage from STAT.
          Chris O'Meara/AP

          Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

          Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

          advertisement

          In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Decentralized clinical trials need collaboration to achieve wider use
          Decentralized clinical trials need collaboration to achieve wider use

          AdobeDespitegroundbreakingadvancesinbasicandclinicalscienceandtechnology,clinicaltrialmethodshavenot

          read more
          Continuity nursing helped my family in our darkest PICU moments
          Continuity nursing helped my family in our darkest PICU moments

          EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

          read more

          Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCJapanesedrugmakerNipponShinyakusaidon